A 1 month, open-label inpatient, randomized cross-over trial assessing the impact of dry powder inhaled insulin (Exubera) on 24-hour glycemic control compared to insulin glargine (Lantus) in patients with type 2 diabetes mellitus who are poorly controlled on a combination of two oral agents

Trial Profile

A 1 month, open-label inpatient, randomized cross-over trial assessing the impact of dry powder inhaled insulin (Exubera) on 24-hour glycemic control compared to insulin glargine (Lantus) in patients with type 2 diabetes mellitus who are poorly controlled on a combination of two oral agents

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2009

At a glance

  • Drugs Insulin; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Jul 2009 Results published in Diabetes, Obesity and Metabolism.
    • 17 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top